Rice Hall James & Associates LLC Invests $4.92 Million in Utah Medical Products, Inc. $UTMD
Rice Hall James & Associates LLC has acquired a new stake in Utah Medical Products, Inc. (NASDAQ:UTMD) by purchasing 71,363 shares valued at approximately $4.92 million, representing about 2.24% of the company. Other institutional investors have also adjusted their holdings, with 69.60% of the stock owned by hedge funds and institutions. Analysts currently hold a consensus "Hold" rating for UTMD, which recently reported quarterly earnings of $0.84 per share and declared a quarterly dividend of $0.31 per share.
Brandes Investment Partners reports 14.9% Utah Medical Products (UTMD) stake
Brandes Investment Partners has filed an amended Schedule 13G, disclosing a 14.92% passive ownership stake in Utah Medical Products Inc., totaling 475,158 common shares. These shares are held across mutual funds and other accounts advised by Brandes, with the Brandes Small Cap Value Fund alone holding 6.87% of the class. The filing indicates shared voting power over 435,111 shares and shared dispositive power over all 475,158 shares, with no sole control reported.
Utah Medical Products (NASDAQ:UTMD) Shares Pass Above 200 Day Moving Average - Time to Sell?
Utah Medical Products (NASDAQ:UTMD) shares have risen above their 200-day moving average, reaching $72.37 against an average of $66.51. The company reported quarterly earnings of $0.84 per share on $8.53 million in revenue and declared a $0.31 quarterly dividend, equivalent to a 1.7% annual yield. Analyst sentiment remains neutral, with a consensus "Hold" rating, despite a recent upgrade from Weiss Ratings.
Renaissance Technologies (UTMD) discloses 5.52% ownership in Utah Medical Products
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 175,814 shares, or 5.52%, in Utah Medical Products Inc. as of June 30, 2026. Both entities hold sole voting and dispositive power over these shares. The filing, a Schedule 13G/A, indicates that certain funds managed by Renaissance Technologies LLC are entitled to receive dividends and proceeds from the sale of these securities.
Trading Systems Reacting to (UTMD) Volatility
This article analyzes the volatility of Utah Medical Products Inc. (NASDAQ: UTMD), highlighting a strong overweight bias across all sentiment horizons. It details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, providing entry and exit points, targets, and stop losses. The analysis points to an exceptional 29.2:1 risk-reward setup for the stock.
UTAH MEDICAL PRODUCTS INC 1H 2026: Revenue $8.53M, EPS $0.84— 10-Q Summary
Utah Medical Products Inc. (UTMD) reported a decline in first-half 2026 financial results, with consolidated revenue falling to $8.53 million and diluted EPS to $0.84 compared to the prior year. This downturn was primarily attributed to the loss of two major customers, slower OEM wins, and reduced international sales. Despite these challenges, domestic sales of Filshie Clip grew, and the company increased inventories and maintained staffing for future product production, though litigation expenses are expected to impact 2026 legal costs.
Utah Medical Products 2Q FY26 net income falls 11.9% to USD 2.69 million; net sales drop 14.3% to USD 8.53 million
Utah Medical Products reported a significant decline in its second-quarter FY26 financial results, with net income falling 11.9% to USD 2.69 million and net sales dropping 14.3% to USD 8.53 million. The company attributed the sales decline to the absence of sales to two major customers and projected a 10%-13% decrease in full-year 2026 net sales due to slower-than-expected biopharma OEM customer sales. Operating income and gross profit also saw reductions, with operating margin narrowing by 1 percentage point and gross margin tightening by 0.4 percentage point due to tariffs.
Utah Medical Products Inc (UTMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article from TradingKey provides an earnings forecast for Utah Medical Products Inc (UTMD), focusing on future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, and P/E ratio, alongside a list of peer companies for comparison. The content indicates an update on August 8, 2026, for financial forecasting, including EPS, Revenue, Net Profit, and EBIT.
Utah Medical Products raises quarterly dividend 1.6%
Utah Medical Products Inc. (Nasdaq:UTMD) has announced a 1.6% increase in its quarterly cash dividend, bringing it to $0.31 per share. The dividend is payable on October 5, 2026, to shareholders recorded by September 17, 2026. The company specializes in developing, manufacturing, and marketing disposable and reusable medical devices for women's and babies' healthcare.
Utah Medical Products, Inc. announces Quarterly dividend, payable on October 05, 2026
Utah Medical Products, Inc. has announced a quarterly dividend of $0.3100 per share. This dividend is payable on October 5, 2026, with an ex-date and record date set for September 17, 2026. The company specializes in developing, manufacturing, and marketing a wide range of disposable and reusable specialty medical devices, particularly for women's healthcare.
Utah Medical Products, Inc. Announces Quarterly Dividend of $0.31 (NASDAQ:UTMD)
Utah Medical Products, Inc. (NASDAQ:UTMD) declared a quarterly dividend of $0.31 per share, payable on October 5th to shareholders of record on September 17th. This dividend represents a 1.7% annualized yield, and the company has consistently increased its dividend for the past three years. Despite a slight dip in stock price, UTMD maintains a market capitalization of $229.91 million and institutional investors hold approximately 69.6% of its shares.
Utah Medical sets 31-cent payment for shareholders on Oct. 5
Utah Medical Products (Nasdaq: UTMD) announced that its Board of Directors has approved a quarterly cash dividend of $0.31 per share of common stock. This dividend, representing a 1.6% increase over the previous year's dividend for the same quarter, is payable on October 5, 2026, to shareholders of record as of September 17, 2026. The company specializes in developing, manufacturing, and marketing medical devices for women and babies.
Utah Medical Products raises quarterly dividend 1.6% By Investing.com
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a quarterly cash dividend of $0.31 per share of common stock, representing a 1.6% increase from the previous year's dividend. The dividend will be payable on October 5, 2026, to shareholders of record as of September 17, 2026. The company specializes in developing, manufacturing, and marketing disposable and reusable specialty medical devices, particularly for women's and babies' healthcare.
How Utah Medical Products Inc. (UTMD) Affects Rotational Strategy Timing
This article from Stock Traders Daily analyzes Utah Medical Products Inc. (UTMD) and its impact on rotational strategy timing. It highlights a near-term strong sentiment possibly influencing mid-term neutrality and a long-term positive bias, noting a mid-channel oscillation pattern. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products (UTMD) reported a significant decline in Q2 2026 earnings and revenue, primarily due to the loss of two major customers, PendoTECH and a China-based distributor. Despite the sales headwinds, the company maintained strong profitability with resilient margins and a robust balance sheet. Management has updated its full-year 2026 revenue outlook to a 10-13% decline, focusing on new product development and expanded customer relationships to mitigate losses.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products, Inc. (UTMD) reported a significant year-over-year decline in Q2 2026 earnings and revenue, primarily due to the loss of two major customers. Diluted EPS decreased by 10.1% and revenues fell by 14.3%, although the company maintained solid profitability with resilient margins despite higher litigation expenses. Management has revised its full-year 2026 revenue outlook to a 10-13% decline, as new product sales have progressed slower than anticipated.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products (UTMD) reported a significant decline in Q2 2026 earnings and revenue, primarily due to the loss of two major customers. Diluted EPS dropped by 10.1% and revenues fell by 14.3% year-over-year, leading the company to lower its full-year revenue outlook. Despite the sales challenges, UTMD maintained a strong balance sheet and solid profitability margins.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products, Inc. (UTMD) reported a decline in Q2 2026 diluted EPS by 10.1% and revenues by 14.3% year-over-year, primarily due to the loss of sales from two major customers, PendoTECH and a China-based distributor. Despite the revenue decline, the company maintained strong profitability with a robust balance sheet and is focusing on new products and customer relationships to offset lost revenue, although the recovery is slower than anticipated. Management updated its full-year 2026 revenue outlook to a 10-13% decline compared to 2025.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products (UTMD) reported a significant decline in Q2 2026 earnings and revenue, primarily due to the loss of two major customers, PendoTECH and a China-based distributor. Diluted EPS decreased by 10.1% and revenues fell by 14.3% year-over-year. Despite the sales decline, the company maintained resilient margins and a strong balance sheet, but has revised its full-year 2026 revenue outlook downwards.
Utah Medical Products Inc (UTMD) Valuation: PE, PB & Fair Value Analysis
Utah Medical Products Inc (UTMD) has a current valuation score of 8.45, placing it 93rd out of 199 companies in the Healthcare Equipment & Supplies industry. Its P/E ratio is 20.98, which is slightly below its recent high but significantly above its recent low. The company has not yet disclosed relevant data for P/B, P/S, and P/CF ratios.
Utah Medical Products Inc (UTMD) Cash Flow
This article provides a detailed cash flow statement for Utah Medical Products Inc (UTMD), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures in millions, showing year-over-year changes and absolute values for various cash flow components. The page also includes an FAQ section explaining key cash flow concepts and UTMD's specific figures for operating cash flow, capital expenditures, and free cash flow in recent periods.
UTMD|Utah Medical Products Inc|Price:69.000|Chg%:+1.860
This article provides a comprehensive stock analysis of Utah Medical Products Inc (UTMD) by TradingKey, highlighting its strong fundamentals and high growth potential. The company is considered fairly valued within the Healthcare Equipment & Supplies industry, despite recent weak stock market performance. The analysis also covers its key products, financial health, dividend history, institutional ownership, and risk assessment dimensions.
Utah Medical Products Inc (UTMD) Financial Health: Profitability & Balance Sheet Analysis
Utah Medical Products Inc (UTMD) has a robust financial score of 9.29, ranking 8th in the Healthcare Equipment & Supplies industry. Despite this strong overall financial health and high operating efficiency, the company experienced a year-over-year decrease of 10.18% in its latest quarterly revenue and a 14.37% decrease in net profit. The detailed financial analysis covers profitability, balance sheet, quality of earnings, operational efficiency, growth potential, and shareholder returns.
Utah Medical Products Inc (UTMD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a detailed historical overview of dividend payouts for Utah Medical Products Inc (UTMD), spanning the last five years. It lists various interim and final cash dividends, including their record dates, payment dates, and ex-dividend dates, along with the gross amount paid per share. The company has distributed a total of $23.17 million in dividends over the past five years.
Utah Medical Products Inc (UTMD) Institutional Confidence
Utah Medical Products Inc (UTMD) has an institutional shareholding score of 7.00, placing it 78th in the Healthcare Equipment & Supplies industry. Institutional investors hold 76.75% of shares, an 8.51% increase quarter-over-quarter. The largest institutional shareholder is Bill Nygren | OAKMX, with 14.11% of outstanding shares.
Utah Medical Products Inc (UTMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Utah Medical Products Inc (UTMD), detailing future EPS and revenue growth estimates. It is presented by TradingKey and includes an overview of the company's financial health, valuation, price momentum, and institutional confidence. The information was updated on July 25, 2026.
Utah Medical Products, Inc. Revenue Breakdown – NASDAQ:UTMD
This article provides a revenue breakdown for Utah Medical Products, Inc. (NASDAQ: UTMD). The company's primary revenue contribution came from the United States, generating $22.76 million last year, slightly down from $23.87 million the prior year. The information is presented under the financial section of its TradingView profile.
Utah Medical Products (UTMD) Stock Margins Slip To 29% Net Profit Challenging Bullish Narratives
Utah Medical Products (UTMD) reported Q2 2026 revenues of $8.5 million and EPS of $0.84, with a trailing 12-month net profit margin of 29%, down from 32.3% previously. The company faces a 5.8% average annual earnings decline over five years, which challenges bullish narratives despite the stock trading significantly below its DCF fair value and having a lower P/E ratio than the industry average. The article discusses both bearish and bullish viewpoints, highlighting the ongoing profitability against a backdrop of softening margins and a gradual decline in earnings.
UTMD|Utah Medical Products Inc|Price:67.140|Chg%:+2.960
Utah Medical Products Inc (UTMD) shows strong fundamentals and high growth potential, despite a weak stock market performance recently. Its valuation is considered fairly valued within the Healthcare Equipment & Supplies industry. The company is in a growing phase with high and stable dividends, though it is seen as overvalued based on its P/E ratio and has experienced institutional selling.
Utah Medical Products Releases Q2 2026 Financial Results
Utah Medical Products, Inc. (UTMD) reported a challenging second quarter in 2026, with diluted earnings per share of $0.84 on $8.5 million in revenue. This represents a 10.5% decline in earnings and a 14.3% drop in revenue compared to the same quarter last year. The medical device manufacturer, specializing in obstetrics, gynecology, and neonatology, noted that its domestic operations generated $5.2 million in revenue and sales of its Filshie Clip System reached $843,000 for the quarter.
Utah Medical Products Releases Q2 2026 Financial Results
Utah Medical Products, Inc. reported weaker second-quarter results for Q2 2026, with diluted earnings of $0.84 per share on revenue of $8.5M. This represents a decline from the prior year, attributed to headwinds across its business segments. The company, specializing in niche medical devices, saw its Filshie Clip System sales reach $843,000 and maintained its historical capital allocation strategy of consistent dividend payments.
Utah Medical: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for Utah Medical. The content is explicitly minimal, containing only the title and a note about being "Powered and protected by Privacy," along with image references. No substantive financial data or details are available in the provided text.
Utah Medical: Q2 Earnings Snapshot
Utah Medical Products Inc. (UTMD) announced its second-quarter earnings, reporting a net income of $2.7 million. On a per-share basis, the company earned 84 cents. The medical device maker also posted revenue of $8.5 million for the period.
Utah Medical reports Q2 sales down 14.3% to $8.53M, net income $2.69M; 1H sales down 12.3%
Utah Medical Products (UTMD) reported Q2 2026 consolidated net sales of $8.529 million, a 14.3% decrease year-over-year, with net income of $2.686 million. First-half sales also fell by 12.3% to $17.252 million. The decline is attributed to the loss of sales from two major former customers and slower-than-expected new biopharma OEM sales, despite the company maintaining a strong cash balance of $87.5 million.
Utah Medical expects zero 2026 sales from two former customers; 10%-13% drop
Utah Medical Products (UTMD) announced significant declines in Q2 and 1H 2026 revenues, down 14.3% and 12.3% respectively, primarily due to zero sales to its two previously largest customers. The company now projects a 10-13% decline in 2026 sales compared to 2025, as efforts to replace lost revenue with new biopharma customers have been slower than anticipated. Despite the revenue challenges and higher litigation costs, UTMD maintains a strong balance sheet with $87.5 million in cash and investments and no debt.
(UTMD) and the Role of Price-Sensitive Allocations
This article provides an in-depth stock analysis for Utah Medical Products Inc. (NASDAQ: UTMD), highlighting divergent sentiment across different time horizons and testing support levels. It outlines three distinct AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis, identifying near-term, mid-term, and long-term support and resistance levels.
(UTMD) and the Role of Price-Sensitive Allocations
This article provides a detailed AI-driven analysis of Utah Medical Products Inc. (NASDAQ: UTMD), highlighting divergent sentiment across different time horizons and indicating choppy market conditions. It presents specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, with defined entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, support, and resistance levels for near-term, mid-term, and long-term outlooks.
(UTMD) and the Role of Price-Sensitive Allocations
An analysis of Utah Medical Products Inc. (NASDAQ: UTMD) reveals weak near-term sentiment but strong mid and long-term outlooks, with an exceptional 27.8:1 risk-reward setup targeting an 8.2% gain. The article offers three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. It also provides multi-timeframe signal analysis, identifying key support and resistance levels for the stock.
Enterprise value to revenue forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article focuses on the enterprise value to revenue forward metric for Utah Medical Products, Inc. (NASDAQ: UTMD). The content appears to be a financial data point or a section from a larger financial analysis tool, providing specific period values for this metric without further explanation. The article also lists various financial and trading resources related to the company.
Price to earnings forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article provides financial data for Utah Medical Products, Inc. (NASDAQ: UTMD), specifically focusing on its forward price-to-earnings ratio. It indicates the stock's performance and financial metrics as of a specific period, noting if the market is closed or if there are no trades. The content highlights TradingView as the platform hosting this data.
Enterprise value to EBITDA forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article provides financial information for Utah Medical Products, Inc. (NASDAQ: UTMD), specifically focusing on its enterprise value to EBITDA forward metric. It highlights the company's stock information on the Nasdaq Stock Market and is presented within the TradingView platform's interface.
Enterprise value to EBIT forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article provides financial information for Utah Medical Products, Inc. (NASDAQ: UTMD), focusing on its enterprise value to EBIT forward. It indicates the latest financial health of the company as of the market close with no trades reported. The content is presented within the TradingView platform, which offers various financial tools and market data.
Form 4 Utah Medical Products Inc For: 1 July By Investing.com
This article from Investing.com reports that a Form 4 for Utah Medical Products Inc. (UTMD) has been filed for July 1st. The filing pertains to insider trading activity for the specified company and date. The article itself provides minimal detail beyond this announcement.
Form 4 Utah Medical Products Inc For: 1 July By Investing.com
This article announces a Form 4 filing for Utah Medical Products Inc. for July 1st. It is a brief report from Investing.com, providing basic information about the filing and noting the company's stock symbol (UTMD) and a slight price increase.
Price to sales forward of Utah Medical Products, Inc. – NASDAQ:UTMD
This article provides financial information for Utah Medical Products, Inc. (NASDAQ: UTMD), specifically focusing on its "Price to sales forward" metric. It appears to be a financial data snippet from TradingView, indicating the company's valuation based on future sales.
Price to book forward of Utah Medical Products, Inc. – NASDAQ:UTMD
The article title indicates that it likely discusses the "Price to book forward" metric for Utah Medical Products, Inc. (NASDAQ:UTMD). However, the body of the article appears to be primarily composed of navigation links and website boilerplate, rather than specific financial analysis. The critical financial data for UTMD regarding this metric is not present within the provided content.
Form 4 Utah Medical Products Inc For: 1 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Utah Medical Products Inc (UTMD) as of July 1st. Form 4s disclose transactions made by company insiders. The article indicates a 3.04% change in UTMD's stock and provides various financial market data and popular news headlines alongside the main announcement.
Form 4 Utah Medical Products Inc For: 1 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Utah Medical Products Inc. on July 1st. The filing pertains to insider transactions, with the article providing the basic headline and indicating that more details might be available within the financial markets platform.
UTAH MEDICAL PRODUCTS (UTMD) director reports 150-share bona fide stock gift
UTAH MEDICAL PRODUCTS INC (UTMD) director Paul O. Richins reported an indirect bona fide gift of 150 shares of Common Stock, valued at $73.07 per share. Following this transaction, Richins's indirect holdings total 20,765 shares, held across various accounts including IRAs and the Richins Family Trust. This transaction is classified as a non-market gift transfer rather than a sale.
Responsive Playbooks and the UTMD Inflection
Utah Medical Products Inc. (NASDAQ: UTMD) is experiencing a breakout with strong near-term sentiment and compelling upside potential. AI-driven models provide tailored trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis. The stock shows no resistance levels above its current price, suggesting further gains.
